Evofem Biosciences, Inc. last reported quarterly results on May 18, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026): revenue of $899,000 (+6.4% year over year) and diluted EPS of -$0.04. It usually reports 44–70 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 44–70 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
May 18, 2026
48 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1
+6.4%
|
-5
-671.7%
|
-0.04
|
|
Mar 11, 2026
70 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
10
+34.6%
|
3
+191.8%
|
0.00
+100.5%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
5
+10.1%
|
-2
+33.7%
|
-0.01
+50.0%
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
5
+16.0%
|
-2
-232.1%
|
-0.01
|
|
May 15, 2025
45 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
1
-76.5%
|
1
+119.9%
|
0.00
+100.0%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
4
-12.1%
|
-2
-103.6%
|
-0.02
-120.0%
|
|
Aug 14, 2024
45 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
May 15, 2024
45 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EVFM (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1618835
- Former names
- Neothetics, Inc. (until Jan 5, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.